<DOC>
	<DOCNO>NCT00017316</DOCNO>
	<brief_summary>Phase II trial study effectiveness combine thalidomide SU5416 treat patient metastatic melanoma . Thalidomide combine SU5416 may stop growth metastatic melanoma stop blood flow tumor .</brief_summary>
	<brief_title>Thalidomide SU5416 Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy thalidomide SU5416 patient metastatic melanoma . II . Determine quantitative qualitative toxic effect regimen patient . III . Evaluate pharmacokinetics regimen patient . IV . Determine complete partial response response duration patient treat regimen . V. Assess disease-free survival 6 month patient treat regimen . OUTLINE : Patients receive SU5416 IV 1 hour twice weekly oral thalidomide daily begin 1 day first dose SU5416 . Treatment repeat every 4 week absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Semaxinib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic melanoma Bidimensionally measurable disease MRI , CT scan , chest xray No active brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : More 12 week Hematopoietic : Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 8.5 g/dL Hepatic : PT/PTT normal Bilirubin great 1.5 mg/dL SGOT/SGPT great 2.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No uncompensated coronary artery disease electrocardiogram physical exam No myocardial infarction severe unstable angina within past 6 month No deep venous thrombosis within past 3 month No arterial thrombosis within past 6 month Pulmonary : No pulmonary embolism within past 6 month Other : HIV negative No active infection No medical , psychological , social problem would preclude study participation No history gastrointestinal disorder would interfere absorption swallow study medication No emotional disorder substance abuse No diabetes mellitus severe peripheral vascular disease Not pregnant nursing Negative pregnancy test Fertile patient must use 2 form effective contraception 4 week , , 4 week study participation PRIOR CONCURRENT THERAPY : Biologic therapy : No 1 prior biologic regimen No concurrent biologic response modifiers No concurrent hematopoietic growth factor support Concurrent epoetin alfa allow Chemotherapy : No concurrent cytotoxic agent Endocrine therapy : No concurrent anticancer hormonal therapy except megestrol acetate appetite stimulation Radiotherapy : No prior large field radiotherapy 20 % total bone marrow No concurrent radiotherapy Surgery : At least 14 day since major surgery No prior major upper gastrointestinal surgery Other : No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2002</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>